Amphastar Pharmaceuticals, Inc. (AMPH) P/E Ratio History
Deep ValueTrading at 9.0x · 5th percentile of 5-year range · Significant discount to historical valuation · Data 2014–2026
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, Amphastar Pharmaceuticals, Inc. (AMPH) trades at a price-to-earnings ratio of 9.0x, with a stock price of $18.33 and trailing twelve-month earnings per share of $1.71.
The current P/E is 57% below its 5-year average of 21.1x. Over the past five years, AMPH's P/E has ranged from a low of 8.6x to a high of 96.0x, placing the current valuation at the 5th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, AMPH trades at a 59% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
The PEG ratio of 0.07 (P/E divided by -34% EPS growth) suggests the stock may be undervalued relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, AMPH trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AMPH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AMPH Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
AMPH P/E vs Peers
Complex generics and injectables peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 31.1 | -Best | -22% | |
| $893M | 141.9 | -Best | +107%Best | |
| $1B | 194.5 | -Best | -79% | |
| $90B | 19.4Lowest | -Best | +49% | |
| $52B | 34.5 | -Best | +87% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
AMPH Historical P/E Data (2014–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $19.60 | $1.66 | 11.8x | -96% |
| FY2025 Q4 | Dec 31 2025 | $26.78 | $2.03 | 13.2x | -95% |
| FY2025 Q3 | - | $26.65 | $2.26 | 11.8x | -96% |
| FY2025 Q2 | Jun 30 2025 | $22.96 | $2.67 | 8.6x | -97% |
| FY2025 Q1 | Mar 31 2025 | $28.99 | $2.76 | 10.5x | -96% |
| FY2024 Q4 | - | $37.13 | $3.06 | 12.1x | -96% |
| FY2024 Q3 | Sep 30 2024 | $48.53 | $3.00 | 16.2x | -94% |
| FY2024 Q2 | Jun 30 2024 | $40.00 | $3.13 | 12.8x | -96% |
| FY2024 Q1 | Mar 31 2024 | $43.91 | $2.89 | 15.2x | -95% |
| FY2023 Q4 | Dec 31 2023 | $61.85 | $2.58 | 24.0x | -92% |
| FY2023 Q3 | Sep 30 2023 | $45.99 | $2.56 | 18.0x | -94% |
| FY2023 Q2 | Jun 30 2023 | $57.47 | $1.95 | 29.5x | -90% |
| FY2023 Q1 | Mar 31 2023 | $37.50 | $1.79 | 20.9x | -93% |
| FY2022 Q4 | Dec 31 2022 | $28.02 | $1.76 | 15.9x | -94% |
| FY2022 Q3 | Sep 30 2022 | $28.10 | $1.49 | 18.9x | -93% |
| FY2022 Q2 | - | $34.79 | $1.78 | 19.5x | -93% |
| FY2022 Q1 | - | $35.90 | $1.61 | 22.3x | -92% |
| FY2021 Q4 | Dec 31 2021 | $23.29 | $1.24 | 18.8x | -93% |
| FY2021 Q3 | - | $19.01 | $0.72 | 26.4x | -91% |
| FY2021 Q2 | Jun 30 2021 | $20.16 | $0.21 | 96.0x | -67% |
| FY2021 Q1 | Mar 31 2021 | $18.32 | $0.05 | 399.1x | +39% |
| FY2020 Q4 | - | $20.11 | $0.03 | 776.4x | +170% |
| FY2020 Q3 | Sep 30 2020 | $18.75 | $0.13 | 139.9x | -51% |
| FY2020 Q2 | - | $22.46 | $0.08 | 267.4x | -7% |
| FY2020 Q1 | - | $14.84 | $1.05 | 14.2x | -95% |
| FY2019 Q4 | - | $19.29 | $0.99 | 19.5x | -93% |
| FY2019 Q3 | Sep 30 2019 | $19.83 | $1.05 | 18.9x | -93% |
| FY2019 Q2 | Jun 30 2019 | $21.11 | $1.07 | 19.7x | -93% |
| FY2019 Q1 | Mar 31 2019 | $20.43 | $0.05 | 407.8x | +42% |
| FY2017 Q4 | Dec 31 2017 | $19.24 | $0.09 | 205.6x | -28% |
| FY2017 Q3 | Sep 30 2017 | $17.87 | $0.00 | 4358.5x | +1418% |
| FY2017 Q2 | Jun 30 2017 | $17.86 | $0.08 | 221.9x | -23% |
| FY2017 Q1 | Mar 31 2017 | $14.50 | $0.19 | 76.1x | -73% |
| FY2016 Q4 | Dec 31 2016 | $18.42 | $0.22 | 83.5x | -71% |
| FY2016 Q3 | Sep 30 2016 | $18.97 | $0.45 | 42.2x | -85% |
| FY2016 Q2 | - | $16.12 | $0.30 | 53.1x | -82% |
| FY2016 Q1 | - | $12.00 | $0.00 | 3333.3x | +1061% |
| FY2014 Q3 | - | $11.65 | $0.04 | 270.9x | -6% |
| FY2014 Q2 | Jun 30 2014 | $10.01 | $0.14 | 70.0x | -76% |
Average P/E for displayed period: 287.2x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AMPH — Frequently Asked Questions
Quick answers to the most common questions about buying AMPH stock.
What is AMPH's P/E ratio?
Amphastar Pharmaceuticals, Inc. (AMPH) trailing twelve-month P/E ratio is 9.0x, based on TTM diluted EPS of $1.71. The 5-year average P/E is 21.1x and the historical range spans 8.6x to 96.0x.
Is AMPH stock overvalued or undervalued?
AMPH trades at 9.0x P/E, below its 5-year average of 21.1x. At the 5th percentile of its historical range (8.6x–96.0x), the stock is priced at a discount to its own history.
Is AMPH stock expensive?
No, AMPH is not expensive on a historical basis. The current P/E of 9.0x is below the 5-year average of 21.1x and sits at the 5th percentile of its valuation range.
What is AMPH's historical P/E range?
Over the past 5 years, AMPH's P/E ratio has ranged from 8.6x to 96.0x, with a median of 18.0x and an average of 21.1x. The current P/E of 9.0x places the stock at the 5th percentile of this range. Full historical data spans 2014–2026.
How does AMPH's P/E compare to the S&P 500?
AMPH trades at 9.0x P/E versus the S&P 500 median of 24.3x. The 63% discount to the market suggests lower growth expectations or perceived higher risk.
How does AMPH's valuation compare to Healthcare peers?
Amphastar Pharmaceuticals, Inc. P/E of 9.0x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is AMPH's PEG ratio?
AMPH PEG ratio is 0.07, based on a P/E of 9.0x and EPS growth of -33.7%. A PEG below 1.0 indicates the valuation is supported by the earnings growth rate — typically considered attractive.
What is AMPH's earnings yield?
AMPH earnings yield is 11.07%, the inverse of its 9.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.